Phase I/IIa Trial of Gemcitabine Plus Trastuzumab and Pertuzumab in Previously Treated Metastatic HER2+ Breast Cancer
Status: Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 27 Jul 2018
Price : $35 *
At a glance
- Drugs Pertuzumab (Primary) ; Gemcitabine; Trastuzumab
- Indications Advanced breast cancer
- Focus Adverse reactions; Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 30 Apr 2018 Planned End Date changed from 1 Sep 2019 to 1 Dec 2019.
- 30 Apr 2018 Planned primary completion date changed from 1 Sep 2018 to 1 Dec 2018.